Expert Opinion on Pharmacotherapy

Article	Citations
Perspectives on the pharmacological management of dystonia	52
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer	31
Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis	31
An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer	28
Fixed-dose combination amlodipine–celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation	28
The pharmacotherapeutic management of pulmonary tuberculosis: an update of the state-of-the-art	24
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes	24
Letter to editor – a response to: ‘efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review’	24
An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date	23
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease	23
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	23
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy	22
An update on the efficacy of Venetoclax for chronic lymphocytic leukemia	22
What must be considered when prescribing hormonal pharmacotherapy for male infertility?	22
Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?	21
Efficacy and safety of Isavuconazole for the treatment of invasive Aspergillus infection - an update of the literature	21
The state-of-the-art pharmacotherapeutic management of neovascular age-related macular degeneration	21
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	20
Pharmacotherapy for post-stroke aphasia: what are the options?	20
Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review	18
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	18
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	17
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	17
Psychedelics for treatment resistant depression: are they game changers?	17
Current optimal pharmacologic therapies for overactive bladder	17

Response to: “the impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19”	16
Pharmacological management of co-morbid obstructive sleep apnoea and insomnia	16
An update on the pharmacological management of acute respiratory distress syndrome	16
A bitter pill to swallow: adjustments to oral contraceptive pill use in polycystic ovary syndrome	16
Examining linaclotide for the treatment of chronic idiopathic constipation	15
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	15
Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy	15
Acalabrutinib in chronic lymphocytic leukemia	14
An update on pharmacotherapies for colorectal cancer: 2023 and beyond	14
An update on the use of pharmacotherapy for opioid-induced bowel dysfunction	14
Novel pharmacotherapy targeting the positive symptoms of schizophrenia	14
Prescribing the right therapy for the treatment of chronic cough: a critical focus on current and investigational options	14
How does a clinician approach the pharmacological management of opioid use disorders in pregnant women and pregnant people?	14
What are the key challenges in the pharmacological management of cholangiocarcinoma?	14
Advances in pharmacotherapy for heart failure and reduced ejection fraction: what’s new in 2024?	13
Evolution of antiplatelet therapy in Japan for the management of cerebrovascular and cardiovascular disease: a survey using data from an insurance claims data information service	13
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	13
Elucidating the mechanisms and efficacy of antimalarial drugs in systemic lupus erythematosus	13
The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus:	12
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	12
Current and promising pharmacotherapeutic options for candidiasis	12
GLP-1 receptor agonists: new kids in the block of renoprotection for people with type 2 diabetes and chronic kidney disease	12
Should we discontinue RAS-inhibitor therapy in patients with advanced CKD?	12
Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation	11
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	11
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children	11
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	11
Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant	11
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B	11
Choosing the appropriate pharmacotherapy for breast cancer during pregnancy: what needs to be considered?	11
The pharmacological treatment and management of hyperhidrosis	11
Dapagliflozin for the treatment of type 2 diabetes mellitus – an update	11
Tafenoquine for the treatment of Plasmodium vivax malaria	11
New pharmacotherapeutic options for oral anticoagulant treatment in atrial fibrillation patients aged 65 and older: factor XIa inhibitors and beyond	10
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases	10
A new role for an old drug: acetazolamide in decompensated heart failure	10
Careful use to minimize adverse events of oral antidiabetic medications in the elderly	10
Aripiprazole IM depot as an option for the treatment of bipolar disorder	10
Pharmacotherapeutic principles of fluid management in heart failure	10
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes	9
Current treatment options for Mycobacterium marinum cutaneous infections	9
An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date	9
Nonselective proteasome inhibitors in multiple myeloma and future perspectives	9
Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases	9
Cytopenic myelofibrosis: prevalence, relevance, and treatment	9
Advances in the drug management of basal cell carcinoma	9
Risk management of medication errors: a novel conceptual framework	9
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	9
The pharmacotherapeutic management of nail unit and acral melanomas	9
Advances in the pharmacological management of bacterial peritonitis	9

Pharmacotherapeutic options for the treatment of menopausal symptoms	9
Immunosuppression in uterus transplantation: from transplant to delivery	9
Evaluating upadacitinib for the treatment of psoriatic arthritis	9
Perspectives on the pharmacological management of complex regional pain syndrome	9
Pharmaceutical management of sexual dysfunction in men on antidepressant therapy	9
How do we address treating the negative symptoms of schizophrenia pharmacologically?	9
Use of antibiotics in hospitalized patients with COVID-19: evolving concepts in a highly dynamic antimicrobial stewardship scenario	9
Advances in pharmacotherapy for head and neck cancer	9
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	8
How should a physician assess medication burden and polypharmacy?	8
Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment	8
Pharmacotherapeutic options for cancer cachexia: emerging drugs and recent approvals	8
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	8
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	8
Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer	8
Cytokine release syndrome after CAR T-cell therapy for B-cell acute lymphoblastic leukemia in children and young adolescents: storms make trees take deeper roots	8
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance	8
An update on pharmacotherapy for fungal infections in allogeneic stem cell transplant recipients	8
Current and emerging treatment modalities for fibrodysplasia ossificans progressiva	8
Pharmacological management of migraine: current strategies and future directions	8
Bexagliflozin for type 2 diabetes: an overview of the data	7
Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	7
Novel pharmacotherapies for the treatment of liposarcoma: a comprehensive update	7
An update on the pharmacotherapy of gout	7
Evaluating fostemsavir as a therapeutic option for patients with HIV	7
Evaluating lemborexant for the treatment of insomnia	7
Asthma management with triple ICS/LABA/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement	7
Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?	7
An overview of micafungin as a treatment option for invasive candidiasis in pediatric patients younger than 4 months old	7
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	7
An update on antifungal resistance in dermatophytosis	7
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	7
An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet–Biedl syndrome	7
An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne	7
Pharmacotherapy considerations for morning symptoms in chronic obstructive pulmonary disease	7
Clinical guidance for unfractionated heparin dosing and monitoring in critically ill patients	7
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	7
Correction	7
Advances in the pharmacological management of cutaneous T-cell lymphoma	7
Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors	7
Letter to the editor – ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	7
An update on emerging pharmacological treatments for meibomian gland dysfunction	7
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	7
Current and emerging pharmacotherapy for recurrent bacterial vaginosis	7
Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia	7
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	7
An update on brivaracetam for the treatment of pediatric partial epilepsy	6
What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?	6
State-of-the-art beta-adrenoreceptor agonists for the treatment of asthma	6
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	6
Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions	6
Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer’s disease: a novel small molecule with disease modifying potential	6
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	6
An update on the current and emerging pharmacotherapy for the treatment of human ascariasis	6
The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?	6
Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies	6
Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease	6
A review of therapeutic failures in late-stage clinical trials	6
Current and emerging pharmacotherapy for menstrual migraine: a narrative review	6
Advances in drug treatments for mesothelioma	6
An update on the pharmacological management of autoimmune hepatitis	6
Guidance for the pharmacological management of COVID-19 in the emergency setting	6
Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?	6
Talazoparib for the treatment of prostate cancer	6
When is it appropriate to treat children with social anxiety, pharmacologically?	6
Advances in small molecule maintenance therapies for high-grade serous ovarian cancer	6
The use of sequential pharmacotherapy for the treatment of acute major depression: a scoping review	6
How to reduce medication errors in patients over the age of 65?	6
Advances in the pharmacological management of non-24-h sleep-wake disorder	6
The pharmacotherapeutic management of allergic rhinitis in people with asthma	6
Advances in the pharmacotherapeutic management of post-traumatic stress disorder	6
Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy	6
Azole resistance in Aspergillus species: promising therapeutic options	6
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia	6
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research	6
Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols	6
Pharmacological strategies for improving the prognosis of glioblastoma	5
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	5
Why are sodium channel modulators not yet pharmacotherapeutic trailblazers for neuropathic pain?	5
What is the real value of metronomic chemotherapy in the treatment of gastrointestinal cancer?	5

Advances in pharmacotherapy for the treatment of peritoneal metastases from colorectal cancer	5
State-of-the-art pharmacological approaches to reduce chorea in Huntington’s disease	5
What are the considerations for the treatment of multidrug resistant Acinetobacter baumannii infections?	5
The Park Sleep subtype in Parkinson’s disease: from concept to clinic	5
Advances in non-biological drugs for the treatment of rheumatoid arthritis	5
The pharmacotherapeutic management of duodenal and gastric ulcers	5
An expert opinion on the pharmacological interventions for Disruptive Mood Dysregulation Disorder (DMDD)	5
Vibegron for the treatment of overactive bladder: a comprehensive update	5
Cannabidiol use in patients with Dravet syndrome and Lennox-Gastaut syndrome: experts’ opinions using a nominal group technique (NGT) approach	5
Complicated urinary tract infections: an update of new and developing antibiotics	5
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	5
New pharmacotherapeutic strategies for drug-resistant Candida infections: a review	5
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	5
Advances in the psychopharmacotherapy of bipolar disorder type I	5
Terlipressin in the management of liver disease	5
Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II	5
Has the utilization of serotonin receptor antagonism made an impact on schizophrenia treatment?	5
Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion	5
An evaluation of sotorasib for the treatment of patients with non–small cell lung cancer with KRASG12C mutations	5
Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review	5
Improving adherence with treatment-resistant hypertension	5
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	5
Efficacy and tolerability of pharmacotherapy for obsessive-compulsive personality disorder: a systematic review of randomized controlled trials	5
Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go?	5
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia	5
An up-to-date overview of the pharmacotherapeutic options for premature ejaculation	5
Zanubrutinib for the treatment of chronic lymphocytic leukemia	5
Pharmacotherapeutic options in the treatment of nocturia: an update on the current oral drug therapies	5
Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?	5
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	5
How useful is chemotherapy for atypical and anaplastic meningiomas?	5
How do you treat obesity in the elderly pharmacologically?	5
Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis	5
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer	5
Exploring odevixibat’s efficacy in alagille syndrome: insights from recent clinical trials and IBAT inhibitor experiences	5
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis	5
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	5
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults	4
How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation	4
Update on current pharmacologic therapies for diabetic retinopathy	4
The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain	4
Advances with pharmacotherapy for the treatment of interstitial lung disease	4
Expanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV	4
Update on the pharmacological treatment of chronic obstructive pulmonary disease	4
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?	4
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	4
Advances in pharmacotherapy for sickle cell disease: what is the current state of play?	4
Selecting appropriate therapy for lower-risk myelodysplastic syndromes: current state and future prospects	4
Identifying the challenges for successful pharmacotherapeutic management of sarcopenia	4
Advances in the pharmacological management of acute myeloid leukemia in adults	4
Promising advances in treatments for the management of idiopathic pulmonary fibrosis	4
How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?	4
Current chemotherapeutic options for the treatment of gestational trophoblastic disease	4
Therapeutic orphans, off-label, pediatric drug development: towards reasonable pharmacotherapy for minors	4
Medications to manage infant pain, distress and end-of-life symptoms in the immediate postpartum period	4
Current pharmacotherapy of cryptosporidiosis: an update of the state-of-the-art	4
Current and emerging treatment modalities for bacterial rhinosinusitis in adults: a comprehensive review	4
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	4
Aztreonam-avibactam for the treatment of intra-abdominal infections	4
What value do cell cycle inhibitors have in the treatment of myelodysplastic syndrome?	4
An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis	4
Rise and fall of decongestants in treating nasal congestion related diseases	4
Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics	4
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	4
PSMA-based therapeutics for prostate cancer	4
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	4
The pharmacological management of treatment-resistant depression: what does the future hold?	4
Emerging therapies targeting growth factors in hepatocellular carcinoma	4
Testosterone replacement therapy: clinical considerations	4
Evaluating rimegepant for the treatment of migraine	4
Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus	4
Current and emerging pharmacotherapeutic strategies for Tourette syndrome	4
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	4
Advances in pharmacotherapy for bronchiectasis in adults	4
Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity	4
The latest emerging drugs for the treatment of diabetic cardiomyopathy	4
Pharmacological management of secondary spinal cord injury	4
Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)	4
Selinexor in multiple myeloma	4
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia	4
Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer	4
Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women	4
The complement system: a novel therapeutic target for age-related macular degeneration	4
Cardiovascular risk of hormone replacement therapy in menopausal women with diabetes: a systematic review and meta-analysis of clinical trials and observational studies	4
Momelotinib in myelofibrosis	4
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	4
Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma	4
Rethinking the use of hypnotics for treatment of insomnia in the elderly	4
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	4
An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer	4
Current advances in the management of cluster headaches	3
Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?	3
Strategies for the diagnosis and management of meningitis in HIV-infected adults in resource limited settings	3
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	3
Evaluating serdexmethylphenidate and dexmethylphenidate capsules as a once-daily treatment option for ADHD	3